WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL: Barclays 26th Annual Global Healthcare Conference: Form ...

Core Viewpoint - Arbutus Biopharma Corporation is actively engaging with investors through participation in two upcoming conferences, highlighting its focus on developing a functional cure for chronic hepatitis B virus (cHBV) infection [1][2]. Group 1: Company Overview - Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company specializing in virology, aiming to develop novel therapeutics for chronic hepatitis B virus (cHBV) [2]. - The company’s strategy involves suppressing HBV DNA, reducing surface antigen, and enhancing HBV-specific immune responses to achieve a functional cure [2]. - Arbutus has a pipeline that includes proprietary compounds such as imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor [2]. Group 2: Clinical Trials - Imdusiran is currently undergoing two Phase 2a combination clinical trials, showing promising clinical data in reducing surface antigen and reawakening HBV-specific immune responses [2]. - AB-101 is in the Phase 1a/1b clinical trial stage, indicating ongoing development efforts for this compound [2]. Group 3: Investor Engagement - The management team of Arbutus will present at the Barclays 26th Annual Global Healthcare Conference on March 12, 2024, and will also participate in the Jefferies Biotech on the Bay Summit on March 13, 2024 [1]. - A live webcast of the Barclays conference presentation will be available, with an archived replay accessible on the Arbutus website for a limited time [1].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 Arbutus Biopharma Corporation (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State or Other ...

Financial Data and Key Metrics Changes - The company ended 2023 with approximately $132 million in cash, cash equivalents, and investments, down from approximately $184 million as of December 31, 2022 [18] - The net cash burn for 2023 was $85.9 million, with expectations for a significant reduction in 2024 to a range of $63 million to $67 million [18][19] Business Line Data and Key Metrics Changes - The company is focusing its pipeline on HBV, with ongoing clinical trials for imdusiran and AB-101 [5][12] - Two Phase 2a clinical trials with imdusiran are currently underway, with data expected throughout 2024 [8][12] Market Data and Key Metrics Changes - The company anticipates reporting data from its clinical trials, including the potential for patients to achieve undetectable surface antigen levels, which is crucial for functional cure [8][12] Company Strategy and Development Direction - The company aims to develop a treatment for chronic HBV patients that achieves at least a 20% functional cure rate, addressing a significant unmet medical need [6][7] - A three-pronged approach is being executed to functionally cure HBV, focusing on combination therapies [7][15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of imdusiran and AB-101 to deliver a functional cure for hepatitis B, with a strong financial position to support ongoing development [19] - The company is committed to advancing its proprietary clinical assets and expects to initiate a third Phase 2a clinical trial in 2024 [20] Other Important Information - The company is involved in ongoing intellectual property litigation against Moderna and Pfizer-BioNTech, with significant developments expected in the coming months [9][10] Q&A Session Summary Question: Can you help frame expectations for the upcoming claim construction order? - Management indicated they are cautious about public comments on the litigation but are looking forward to the judge's ruling expected within 60 days of February 8 [21][24] Question: Is there an opportunity for a summary judgment before going to trial? - Management confirmed that there is a potential for a summary judgment in late summer, but timelines are subject to change [25][26] Question: Can you elaborate on the PD-L1 antibody study designs? - Management discussed the rationale for targeting PD-L1 over PD-1, emphasizing the upregulation of PD-L1 in hepatocytes and the strategic choice of small molecule agents [27][29] Question: When do you plan to re-engage with the FDA on AB-101? - Management stated they intend to re-engage with the FDA once sufficient data is available to support their case [33][34] Question: What do you need to see from the results to move forward with VTP-300? - Management indicated that they will evaluate the data as it comes in and may need to see nivo data before proceeding with VTP-300 [35][36] Question: Can you discuss the design of the new 203 Phase 2a study with durvalumab? - Management noted that details will be shared once the first subject is enrolled, with the study aimed at informing future studies with imdusiran [38][39]

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.12 per share when it actually produced a loss of $0.12, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Arbutus, which belongs to the Z ...

WARMINSTER, Pa., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024. The schedule for the press release and conference call/webcast are as follows: •Q4 and Year ...

Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a third Phase 2a clinical trial evaluating imdusiran and an approved PD-L1 monoclonal antibody expected in 1H 2024 Preliminary data from a Phase 1a/1b clinical trial with AB-101, our oral PD-L1 inhibitor, expected in 1H 2024 Claim construction hearing for Moderna LNP litigation scheduled for February 8, 2024 Strong ...

Arbutus Biopharma Corporation. (NASDAQ:ABUS) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Lisa Caperelli - VP of IR Bill Collier - President, CEO and Director David Hastings - CFO and CAO Karen Sims - Chief Medical Officer Michael Sofia - Chief Scientific Officer Michael McElhaugh - Chief Operating Officer Conference Call Participants Roy Buchanan - JMP Operator Good day, and thank you for standing by. Welcome to the Arbutus Third Quarter Corporate and Financial Update C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) British Columbia, Canada 98-0597776 (State ...

Corporate Presentation NASDAQ: ABUS www.arbutusbio.com August 3, 2023 ...